| Literature DB >> 15151704 |
Eva Mann1, Michael Koller, Christian Mann, Tischa van der Cammen, Johann Steurer.
Abstract
BACKGROUND: Most comprehensive geriatric assessment (CGA) programs refer to hospital-based settings. However the body of geriatric healthcare is provided by general practitioners in their office. Structured geriatric problem detection by means of assessment instruments is crucial for efficient geriatric care giving in the community.Entities:
Year: 2004 PMID: 15151704 PMCID: PMC434505 DOI: 10.1186/1471-2318-4-4
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Geriatric assessment chart
| Visual acuity | Jaeger's test [37] | ≤20/40 | Referral to ophthalmologist |
| Hearing acuity | Whisper test [38] | Failure to correctly repeat 3 whispered numbers | Removal of ear wax |
| Urinary incontinence | IKO-4-Test [39] | 4 defined questions ≥1 question answered positive | Change of existing drug prescription |
| Depression | Geriatric depression scale, short version (GDS 4) [33] | 4 defined questions ≥1 question answered positive | New antidepressant drug therapy |
| Cognitive impairment | Memory Assessment Clinics Questionnaire (MAC-Q) [40] | 6 defined questions (Score range 7 – 35) Score ≥25 suggestive of cognitive impairment | Follow-up examination in 6 months¶ |
| ADL and IADL † | Katz's ADL scale (4 questions) [41] | Score ≤7 impairment of functioning in daily living (total score 0–9). | Planning of in-depth exploration by GP |
| Psychosocial circumstances | Do you have trustworthy persons giving you assistance at home? [43] | Yes/No | Contact with community nurse, neighbours or relatives |
| Sleep disorder | Do you suffer from frequent sleeping problems? | Yes/No | Non-Drug therapy |
| Influenza and pneumococcal Immunisation | Influenza vaccination within a one-year period [24] | Yes/No | Influenza or pneumococcal vaccination |
| Fall risk assessment | History of falls | Fall within last 6 months | Exploration of drug prescription |
| Cardiovascular risk assessment | Lipid profile (mmol/l) [47,48] | Chol > 5.95 mmol/l | Change or onset of antilipidemic drug treatment |
| Medication history | Number of prescribed drugs | >5 prescription drugs | |
| Hospital stay | Hospital stay within a 5-months period [43] | ||
| Nutrition | Body mass index | BMI normal range for the elderly 24 – 29, Waid Guide [52] | Planning of in-depth exploration by GP |
| Osteoporosis risk factors | 9 items risk factor checklist [53] | Female sex | Calcium and Vitamin D |
† Basic and instrumental activities of daily living. ¶ Only for borderline cases (MAC-Q 22–24 points)
Number of disease management actions undertaken by the GPs following positive or negative test results.
| No | % † | 95% CI | No | % ‡ | 95% CI | ||
| Osteoporosis risk (n = 115) | 62 | 76.5 | 57.4 to 88.8 | 21 | 61.7 | 30.8 to 85.4 | 0.51 |
| Urinary incontinence (n = 112) | 51 | 67.1 | 52.2 to 79.2 | 3 | 8.3 | 2.6 to 23.3 | 0.33 |
| Hearing loss (n = 114) | 38 | 65.5 | 48.7 to 79.2 | 1 | 1.8 | 0.2 to 15.3 | 0.17 |
| Pneumococcal vaccination longer than 3 years ago (n = 113) | 19 | 20.4 | 7.2 to 46.2 | 4 | 20.0 | 5.8 to 50.4 | 0.17 |
| Fall risk or balance and gait difficulties (n = 115) | 22 | 45.8 | 28.1 to 64.7 | 16 | 23.9 | 7.1 to 56.3 | 0.14 |
| Sleep disorder (n = 114) | 31 | 73.8 | 52.0 to 88.0 | 2 | 2.8 | 0.6 to 28.1 | 0.11 |
| Influenza vaccination longer than one year ago (n = 114) | 8 | 15.4 | 2.2 to 60.4 | 12 | 19,4 | 7.8 to 40.6 | 0.08 |
| Low vision (n = 110) | 21 | 65.6 | 43.2 to 82.8 | 8 | 10.3 | 3.4 to 27.3 | 0.08 |
| Cognitive impairment (n = 114) | 12 | 19.1 | 10.3 to 32.5 | 1 | 2.0 | 0.2 to 17.0 | 0.06 |
| Depression (n = 114) | 20 | 58.8 | 29.7 to 82.9 | 1 | 1.3 | 0.1 to 12.6 | 0.05 |
| Hyperlipidemia at assessment (n = 113) | 9 | 13.6 | 5.5 to 30.0 | 0 | 0 | 0.04 | |
| Hypertension at assessment (n = 111) | 4 | 7.5 | 3.4 to 16.0 | 0 | 0 | 0.02 | |
| Psychosocial deprivation (n = 113) | 6 | 75.0 | 37.0 to 93.9 | 7 | 6.6 | 1.9 to 21.3 | 0.01 |
| Hyperglycemia at assessment (n = 112) | 2 | 7.1 | 1.4 to 29.4 | 0 | 0 | 0 | 0.01 |
§Product score to generate a rank order of practical relevance: Product of prevalence times the proportion of any actions following either positive or negative test results. † In relation to prevalences displayed in Table 3. ‡ In relation to negative tests [total (n) – number of positive tests] in Table 3.
Patients baseline characteristics as recorded in the CGA chart (n = 115)
| Age years (mean, SD) | 77.9 (3.8) |
| Female sex (%) | 85 (73.9%) |
| Number of geriatric problems (mean, SD) | 6.4 (2.7) |
| Social circumstances | |
| Living at home (No, %) | 113 (98%) |
| Living alone (No, %) | 53 (46%) |
| No limitations in Instrumental Activities of Daily Living (IADL) | 94 (81.8%) |
| Hospital stay within a 5-months period | 30 (26.5%) |
| Nutrition | |
| BMI, mean (mean, SD) | 26.4 (4.5) |
| Overweight (BMI > 29) | 31 (27.0%) |
| Underweight (BMI < 24) | 38 (33%) |
| Cardiovascular risk factors other than age ¶ | 84 (73.0%) |
| Hypertension | 68 (60.2%) |
| Diabetes | 21 (18.6%) |
| Hyperlipidemia | 39 (34.5%) |
| Smoking | 7 (6.2%) |
| Multiple medication use | |
| >5 prescription drugs | 47 (41.2%) |
| >3 over the counter drugs | 3 (6.3%) |
| Fall within a 5-months period | 28 (25.0%) |
¶ Refer to risk factors in the medical history of the patient known prior to CGA
Prevalence of positive assessment test results
| Pneumococcal vaccination longer than three years ago (n = 113) | 93 | 82.3% | 65.4 to 92.0% |
| Osteoporosis risk (n = 115) | 81 | 70.4% | 57.0% to 81.1% |
| Urinary incontinence (n = 112) | 76 | 67.9% | 53.8% to 79.3% |
| Hyperlipidemia at assessment (n = 113) | 66 | 57.4% | 46.7% to 67.4% |
| Cognitive impairment (n = 114) | 63 | 55.2% | 41.7% to 68.1% |
| Hearing loss (n = 114) | 58 | 50.9% | 38.7% to 62.9% |
| Hypertension at assessment (n = 111) | 53 | 47.8% | 28.1 to 68.1% |
| Last influenza vaccination longer than one year ago (n = 114) | 52 | 45.6% | 7.1% to 54.4% |
| Fall risk or balance and gait difficulties (n = 115) | 48 | 41.7% | 34.5 to 49.4% |
| Sleep disorder (n = 114) | 42 | 36.8% | 24.6% to 51.0% |
| Depression (n = 114) | 34 | 29.8% | 19.1% to 43.3% |
| Low vision (n = 110) | 32 | 29.1% | 13.8 to 51.3% |
| Hyperglycemia at assessment (n = 112) | 28 | 25.0% | 16.2% to 36.6% |
| Psychosocial deprivation (n = 113) | 8 | 7.1% | 3.1% to 15.3% |
Frequencies of detailed management actions undertaken by the physicians following positive or negative screening tests.
| No | % † | No | % † | ||
| Osteoporosis risk assessment (n = 115) | 83 | 72.1 | DXA bone measurement | 76 | 66.1 |
| New prescription of Vitamin D3 and Calcium | 58 | 50.4 | |||
| New estrogen replacement therapy | 1 | 0.9 | |||
| Bisphosophonate | 22 | 19.1 | |||
| Calcitonin | 0 | 0 | |||
| Selective estrogen-receptor modulator therapy | 1 | 0.9 | |||
| Urinary incontinence (n = 112) | 54 | 47.0 | Pelvic floor muscle training | 21 | 18.8 |
| Change of drug prescription | 7 | 6.3 | |||
| Planning of in depth exploration by GP | 17 | 15.2 | |||
| New drug prescription | 15 | 13.4 | |||
| Referral to urologist or gynaecologist | 11 | 9.8 | |||
| Hearing loss (n = 114) | 39 | 33.9 | Removal of ear wax | 15 | 13.2 |
| Referral to otolaryngologist | 29 | 25.4 | |||
| Fall risk or balance and gait difficulties (n = 115) | 38 | 33.1 | Change of drug prescription | 4 | 3.5 |
| Hip protector | 3 | 2.6 | |||
| Environmental source exploration | 20 | 17.4 | |||
| Information on safer footwear | 25 | 21.7 | |||
| Instructed exercise training | 7 | 6.1 | |||
| Planning of in-depth exploration by GP | 5 | 4.3 | |||
| Sleep disorder (n = 114) | 33 | 28.7 | New drug prescription | 16 | 14.0 |
| Change of drug prescription | 2 | 1.8 | |||
| Non- drug therapy | 13 | 11.4 | |||
| Planning of in-depth exploration by GP | 5 | 4.4 | |||
| Low vision (n = 110) | 29 | 26.4 | Referral to ophthalmologist | 29 | 26.4 |
| Pneumococcal vaccination longer than 3 years ago (n = 113) | 23 | 20.0 | Pneumococcal vaccination | 23 | 20.4 |
| Depression (n = 114) | 21 | 18.3 | New antidepressant drug therapy | 7 | 6.1 |
| Change of drug prescription | 2 | 1.8 | |||
| Non-drug treatment | 10 | 8.8 | |||
| Planning of in-depth exploration by GP | 9 | 7.9 | |||
| Referral to psychiatrist | 1 | 0.9 | |||
| Influenza vaccination longer than one year ago (n = 114) | 20 | 17.4 | Influenza vaccination | 20 | 17.4 |
| Psychosocial deprivation (n = 113) | 14 | 12.3 | Contact with relatives | 7 | 6.1 |
| Contact with neighbours | 4 | 3.5 | |||
| Contact with community nurse | 6 | 5.3 | |||
| Contact with social worker | 1 | 0.9 | |||
| Cognitive impairment (n = 114) | 13 | 11.4 | Follow up in six months | 37 | 32.5 |
| Referral to neurologist/psychiatrist | 13 | 11.4 | |||
| Hyperlipidemia at assessment (n = 113) | 9 | 7.9 | Antilipidemic drug treatment | 9 | 7.9 |
| Hypertension at assessment (n = 111) | 4 | 3.6 | New or additional drug prescription | 4 | 3.6 |
| Hyperglycemia at assessment (n = 112) | 2 | 1.8 | New or additional drug prescription | 2 | 1.8 |
† Percentage related to all participants ¶ Multiple notations possible
Independent significant associations of risk of the particular screening item by age and sex
| Odds ratio * | 95% CI | Odds ratio * | 95% CI | |
| Fall risk | 1.11 | 1.001 to 1.23 | 2.15 | 1.06 to 4.37 |
| Cognitive impairment | n.s. | 2.28 | 1.10 to 4.73 | |
| Depression | n.s. | 5.16 | 1.64 to 16.25 | |
| Visual impairment | 1.18 | 1.04 to 1.34 | 2.93 | 1.29 to 6.68 |
* Odds ratios are deviated from logistic regression models taking into account cluster sample design. They represent the increased odds of being at risk for a presented item associated with age (by each year) or by being female.